Novartis AG stock (CH0012005267): shares gain after positive trial updates and fresh Jefferies target context

Novartis shares firmed on the NYSE on 06/04/2026, helped by positive clinical and regulatory news flow on key drugs, while Jefferies reiterated its CHF 110 target and Neutral stance, keeping valuation in focus for the Swiss blue chip.

Novartis shares continued to attract attention in Switzerland and the United States after a solid session on the New York Stock Exchange on 06/04/2026, where the American depositary receipts of Novartis AG (ticker: NVS) closed up by about 3.12% at USD 148.40, according to TradingKey and GuruFocus as of 06/04/2026.TradingKey as of 06/04/2026

The rebound came as investors reacted to favorable clinical trial results and regulatory progress for several key therapies, including Vanrafia, Cosentyx and Scemblix, underpinning sentiment toward the Swiss pharmaceutical group listed on SIX Swiss Exchange under the symbol NOVN, while its primary listing and headquarters remain anchored in Switzerland.GuruFocus as of 06/04/2026

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Basel, Switzerland
• Core markets: Europe, United States, emerging markets
• Key revenue drivers: Innovative prescription medicines in oncology, immunology, cardiovascular, neuroscience and rare diseases
• Home exchange/listing venue: SIX Swiss Exchange (NOVN)
• Trading currency: CHF

Novartis AG: core business model

Novartis focuses on patented prescription medicines, concentrating its resources on specialty and innovative therapies that aim to address high unmet medical needs across oncology, immunology, cardiovascular and neuroscience, with sales largely driven by blockbuster brands and late-stage pipeline assets.

Valuation metrics and multiples for Novartis AG

With Novartis shares advancing on 06/04/2026, valuation remains a key discussion point for investors evaluating the Swiss large cap pharmaceutical stock in relation to both its earnings profile and its peers in the European healthcare sector.

According to MarketScreener, Jefferies on 06/04/2026 reaffirmed a Neutral rating on Novartis and maintained its 12-month price target at CHF 110, highlighting the bank’s view on the company’s risk-reward balance at that time.MarketScreener as of 06/04/2026

On the same MarketScreener page, the most recently referenced last close price before the latest move was shown at USD 143.61 for NVS on the NYSE, underscoring that the American listing offers significant liquidity for international investors alongside the shares traded in Swiss francs in Zurich.MarketScreener as of 06/04/2026

Conclusion

Novartis shares gained ground on 06/04/2026 on the back of positive clinical and regulatory news around key therapies, while trading activity on the NYSE and SIX highlighted its status as a major Swiss healthcare name with global investor interest.

At the same time, Jefferies’ reaffirmed Neutral rating and CHF 110 price target as of 06/04/2026 underlines that, despite the recent share price move, valuation considerations remain central to the investment debate around Novartis in the broader pharmaceuticals and biotechnology sector.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.